Use este identificador para citar ou linkar para este item:
https://www.arca.fiocruz.br/handle/icict/35191
Tipo de documento
ArtigoDireito Autoral
Acesso restrito
Coleções
Metadata
Mostrar registro completo
CROSS-SPECIES IMMUNE RECOGNITION BETWEEN PLASMODIUM VIVAX DUFFY BINDING PROTEIN ANTIBODIES AND THE PLASMODIUM FALCIPARUM SURFACE ANTIGEN VAR2CSA
Autor(es)
Gnidehou, Sédami
Mitran, Catherine J.
Arango, Eliana
Banman, Shanna
Mena, Angie
Medawar, Evelyn
Lima, Barbara Andreza Soares
Doritchamou, Justin
Rajwani, Jahanara
Jin, Albert
Gavina, Kenneth
Ntumngia, Francis
Duffy, Patrick
Narum, David
Ndam, Nicaise Tuikue
Nielsen, Morten A.
Salanti, Ali
Kano, Flora Satiko
Carvalho, Luzia Helena de
Adams, John H.
Maestre, Amanda
Good, Michael F.
Yanow, Stephanie K.
Mitran, Catherine J.
Arango, Eliana
Banman, Shanna
Mena, Angie
Medawar, Evelyn
Lima, Barbara Andreza Soares
Doritchamou, Justin
Rajwani, Jahanara
Jin, Albert
Gavina, Kenneth
Ntumngia, Francis
Duffy, Patrick
Narum, David
Ndam, Nicaise Tuikue
Nielsen, Morten A.
Salanti, Ali
Kano, Flora Satiko
Carvalho, Luzia Helena de
Adams, John H.
Maestre, Amanda
Good, Michael F.
Yanow, Stephanie K.
Afiliação
University of Alberta. Department of Biology. Edmonton, Canada.
University of Alberta. School of Public Health. Edmonton, Canada.
Grupo Salud y Comunidad. Facultad de Medicina. Medellín, Colombia.
University of Alberta. School of Public Health. Edmonton, Canada.
University of Alberta. School of Public Health. Edmonton, Canada.
University of Alberta. School of Public Health. Edmonton, Canada.
Fundação Oswaldo Cruz. Instituto Rene Rachou. Belo Horizonte, MG, Brasil.
National Institute of Allergy and Infectious Diseases. Rockville, Maryland.
University of Alberta. School of Public Health. Edmonton, Canada.
University of Alberta. School of Public Health. Edmonton, Canada.
University of Alberta. Department of Medical Microbiology and Immunology. Edmonton, Canada.
University of South Florida. Tampa.
National Institute of Allergy and Infectious Diseases. Rockville, Maryland.
National Institute of Allergy and Infectious Diseases. Rockville, Maryland.
Institut de Recherche pour le Développement. Paris, France.
Department of Immunology and Microbiology. Center for Medical Parasitology. University of Copenhagen. Denmark.
Department of Immunology and Microbiology. Center for Medical Parasitology. University of Copenhagen. Denmark.
Fundação Oswaldo Cruz. Instituto Rene Rachou. Belo Horizonte, MG, Brasil.
Fundação Oswaldo Cruz. Instituto Rene Rachou. Belo Horizonte, MG, Brasil.
University of South Florida. Tampa.
Grupo Salud y Comunidad. Facultad de Medicina. Medellín, Colombia.
Institute for Glycomics. Griffith University. Gold Coast, Australia.
University of Alberta. School of Public Health. Edmonton, Canada / University of Alberta. Department of Medical Microbiology and Immunology. Edmonton, Canada.
University of Alberta. School of Public Health. Edmonton, Canada.
Grupo Salud y Comunidad. Facultad de Medicina. Medellín, Colombia.
University of Alberta. School of Public Health. Edmonton, Canada.
University of Alberta. School of Public Health. Edmonton, Canada.
University of Alberta. School of Public Health. Edmonton, Canada.
Fundação Oswaldo Cruz. Instituto Rene Rachou. Belo Horizonte, MG, Brasil.
National Institute of Allergy and Infectious Diseases. Rockville, Maryland.
University of Alberta. School of Public Health. Edmonton, Canada.
University of Alberta. School of Public Health. Edmonton, Canada.
University of Alberta. Department of Medical Microbiology and Immunology. Edmonton, Canada.
University of South Florida. Tampa.
National Institute of Allergy and Infectious Diseases. Rockville, Maryland.
National Institute of Allergy and Infectious Diseases. Rockville, Maryland.
Institut de Recherche pour le Développement. Paris, France.
Department of Immunology and Microbiology. Center for Medical Parasitology. University of Copenhagen. Denmark.
Department of Immunology and Microbiology. Center for Medical Parasitology. University of Copenhagen. Denmark.
Fundação Oswaldo Cruz. Instituto Rene Rachou. Belo Horizonte, MG, Brasil.
Fundação Oswaldo Cruz. Instituto Rene Rachou. Belo Horizonte, MG, Brasil.
University of South Florida. Tampa.
Grupo Salud y Comunidad. Facultad de Medicina. Medellín, Colombia.
Institute for Glycomics. Griffith University. Gold Coast, Australia.
University of Alberta. School of Public Health. Edmonton, Canada / University of Alberta. Department of Medical Microbiology and Immunology. Edmonton, Canada.
Resumo em Inglês
Background: In pregnancy, Plasmodium falciparum parasites express the surface antigen VAR2CSA, which mediates adherence of red blood cells to chondroitin sulfate A (CSA) in the placenta. VAR2CSA antibodies are generally acquired during infection in pregnancy and are associated with protection from placental malaria. We observed previously that men and children in Colombia also had antibodies to VAR2CSA, but the origin of these antibodies was unknown. Here, we tested whether infection with Plasmodium vivax is an alternative mechanism of acquisition of VAR2CSA antibodies.
Methods: We analyzed sera from nonpregnant Colombians and Brazilians exposed to P. vivax and monoclonal antibodies raised against P. vivax Duffy binding protein (PvDBP). Cross-reactivity to VAR2CSA was characterized by enzyme-linked immunosorbent assay, immunofluorescence assay, and flow cytometry, and antibodies were tested for inhibition of parasite binding to CSA.
Results: Over 50% of individuals had antibodies that recognized VAR2CSA. Affinity-purified PvDBP human antibodies and a PvDBP monoclonal antibody recognized VAR2CSA, showing that PvDBP can give rise to cross-reactive antibodies. Importantly, the monoclonal antibody inhibited parasite binding to CSA, which is the primary in vitro correlate of protection from placental malaria.
Conclusions: These data suggest that PvDBP induces antibodies that functionally recognize VAR2CSA, revealing a novel mechanism of cross-species immune recognition to falciparum malaria.
Compartilhar